RA Medical Systems (NYSE:RMED) had its price objective dropped by equities research analysts at Maxim Group to $15.00 in a research note issued to investors on Friday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 128.31% from the stock’s previous close.
Separately, Zacks Investment Research downgraded shares of RA Medical Systems from a “hold” rating to a “sell” rating in a research note on Tuesday, December 25th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. RA Medical Systems has an average rating of “Buy” and a consensus price target of $18.75.
Shares of NYSE RMED opened at $6.57 on Friday. RA Medical Systems has a twelve month low of $6.00 and a twelve month high of $22.00.
RA Medical Systems (NYSE:RMED) last announced its earnings results on Thursday, March 14th. The company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.83). Sell-side analysts forecast that RA Medical Systems will post -2.26 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of RA Medical Systems during the fourth quarter worth about $98,000. Marshall Wace North America L.P. bought a new stake in shares of RA Medical Systems during the third quarter worth about $268,000. Sit Investment Associates Inc. increased its position in shares of RA Medical Systems by 161.4% during the fourth quarter. Sit Investment Associates Inc. now owns 27,450 shares of the company’s stock worth $218,000 after acquiring an additional 16,950 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in shares of RA Medical Systems during the third quarter worth about $455,000. Finally, Dean Capital Investments Management LLC bought a new stake in shares of RA Medical Systems during the third quarter worth about $546,000. 31.87% of the stock is owned by institutional investors.
About RA Medical Systems
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Featured Article: How Short Selling Works
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.